Ignite Creation Date:
2025-12-24 @ 11:53 AM
Ignite Modification Date:
2025-12-31 @ 4:16 PM
Study NCT ID:
NCT01311661
Status:
COMPLETED
Last Update Posted:
2014-05-01
First Post:
2011-03-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001249', 'term': 'Asthma'}], 'ancestors': [{'id': 'D001982', 'term': 'Bronchial Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012130', 'term': 'Respiratory Hypersensitivity'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clintriage.rdg@boehringer-ingelheim.com', 'phone': '1-800-243-0127', 'title': 'Boehringer Ingelheim Call Center', 'organization': 'Boehringer Ingelheim Pharmaceuticals'}, 'certainAgreement': {'otherDetails': 'Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '3 weeks treatment period + 12 days', 'description': 'Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).', 'otherNumAtRisk': 201, 'otherNumAffected': 0, 'seriousNumAtRisk': 201, 'seriousNumAffected': 2}, {'id': 'EG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.', 'otherNumAtRisk': 101, 'otherNumAffected': 0, 'seriousNumAtRisk': 101, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.', 'otherNumAtRisk': 101, 'otherNumAffected': 0, 'seriousNumAtRisk': 101, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.', 'otherNumAtRisk': 101, 'otherNumAffected': 0, 'seriousNumAtRisk': 101, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.', 'otherNumAtRisk': 102, 'otherNumAffected': 0, 'seriousNumAtRisk': 102, 'seriousNumAffected': 0}], 'seriousEvents': [{'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 201, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 101, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 102, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 201, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 102, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Concussion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 201, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 101, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 102, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 201, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 101, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 102, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 201, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 101, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 102, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}, {'term': 'Meniscus lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 201, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 101, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 102, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 14.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period', 'denoms': [{'units': 'Participants', 'counts': [{'value': '200', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.022', 'spread': '0.020', 'groupId': 'OG000'}, {'value': '0.213', 'spread': '0.024', 'groupId': 'OG001'}, {'value': '0.173', 'spread': '0.024', 'groupId': 'OG002'}, {'value': '0.250', 'spread': '0.024', 'groupId': 'OG003'}, {'value': '0.231', 'spread': '0.024', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.191', 'ciLowerLimit': '0.152', 'ciUpperLimit': '0.229', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.150', 'ciLowerLimit': '0.111', 'ciUpperLimit': '0.189', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.228', 'ciLowerLimit': '0.190', 'ciUpperLimit': '0.266', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.209', 'ciLowerLimit': '0.170', 'ciUpperLimit': '0.247', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS). FAS is defined as all patients in the treated set for whom the baseline (pre-dose) value is available, and who have a value for the primary endpoint for at least one crossover period.'}, {'type': 'SECONDARY', 'title': 'FEV1 Area Under Curve 0-12 Hours (AUC 0-12h) Response at the End of Each Treatment Period', 'denoms': [{'units': 'Participants', 'counts': [{'value': '200', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.052', 'spread': '0.020', 'groupId': 'OG000'}, {'value': '0.242', 'spread': '0.024', 'groupId': 'OG001'}, {'value': '0.212', 'spread': '0.024', 'groupId': 'OG002'}, {'value': '0.266', 'spread': '0.024', 'groupId': 'OG003'}, {'value': '0.272', 'spread': '0.024', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.190', 'ciLowerLimit': '0.150', 'ciUpperLimit': '0.229', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.160', 'ciLowerLimit': '0.121', 'ciUpperLimit': '0.199', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.214', 'ciLowerLimit': '0.175', 'ciUpperLimit': '0.253', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.219', 'ciLowerLimit': '0.181', 'ciUpperLimit': '0.258', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.020', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'FEV1 Area Under Curve 12-24 Hours (AUC 12-24h) Response at the End of Each Treatment Period', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.010', 'spread': '0.020', 'groupId': 'OG000'}, {'value': '0.186', 'spread': '0.025', 'groupId': 'OG001'}, {'value': '0.135', 'spread': '0.025', 'groupId': 'OG002'}, {'value': '0.233', 'spread': '0.025', 'groupId': 'OG003'}, {'value': '0.189', 'spread': '0.025', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.196', 'ciLowerLimit': '0.153', 'ciUpperLimit': '0.238', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.144', 'ciLowerLimit': '0.102', 'ciUpperLimit': '0.187', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.242', 'ciLowerLimit': '0.200', 'ciUpperLimit': '0.285', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.198', 'ciLowerLimit': '0.156', 'ciUpperLimit': '0.241', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Peak FEV1 Within 24 Hours Post-dose Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.227', 'spread': '0.021', 'groupId': 'OG000'}, {'value': '0.410', 'spread': '0.027', 'groupId': 'OG001'}, {'value': '0.380', 'spread': '0.027', 'groupId': 'OG002'}, {'value': '0.449', 'spread': '0.027', 'groupId': 'OG003'}, {'value': '0.437', 'spread': '0.026', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.183', 'ciLowerLimit': '0.138', 'ciUpperLimit': '0.228', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.023', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.153', 'ciLowerLimit': '0.108', 'ciUpperLimit': '0.198', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.023', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.222', 'ciLowerLimit': '0.177', 'ciUpperLimit': '0.267', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.023', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.210', 'ciLowerLimit': '0.165', 'ciUpperLimit': '0.255', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.023', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Trough FEV1 Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.033', 'spread': '0.022', 'groupId': 'OG000'}, {'value': '0.189', 'spread': '0.027', 'groupId': 'OG001'}, {'value': '0.134', 'spread': '0.027', 'groupId': 'OG002'}, {'value': '0.229', 'spread': '0.027', 'groupId': 'OG003'}, {'value': '0.205', 'spread': '0.027', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.156', 'ciLowerLimit': '0.109', 'ciUpperLimit': '0.203', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.101', 'ciLowerLimit': '0.054', 'ciUpperLimit': '0.148', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.196', 'ciLowerLimit': '0.149', 'ciUpperLimit': '0.243', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.172', 'ciLowerLimit': '0.125', 'ciUpperLimit': '0.219', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '200', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.004', 'spread': '0.022', 'groupId': 'OG000'}, {'value': '0.132', 'spread': '0.027', 'groupId': 'OG001'}, {'value': '0.119', 'spread': '0.027', 'groupId': 'OG002'}, {'value': '0.138', 'spread': '0.026', 'groupId': 'OG003'}, {'value': '0.143', 'spread': '0.026', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.136', 'ciLowerLimit': '0.091', 'ciUpperLimit': '0.180', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.023', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.122', 'ciLowerLimit': '0.078', 'ciUpperLimit': '0.167', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.023', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.142', 'ciLowerLimit': '0.098', 'ciUpperLimit': '0.186', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.147', 'ciLowerLimit': '0.103', 'ciUpperLimit': '0.191', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.056', 'spread': '0.023', 'groupId': 'OG000'}, {'value': '0.102', 'spread': '0.028', 'groupId': 'OG001'}, {'value': '0.081', 'spread': '0.028', 'groupId': 'OG002'}, {'value': '0.114', 'spread': '0.028', 'groupId': 'OG003'}, {'value': '0.079', 'spread': '0.028', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.158', 'ciLowerLimit': '0.110', 'ciUpperLimit': '0.206', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.137', 'ciLowerLimit': '0.090', 'ciUpperLimit': '0.185', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.170', 'ciLowerLimit': '0.123', 'ciUpperLimit': '0.218', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.135', 'ciLowerLimit': '0.087', 'ciUpperLimit': '0.182', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.024', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '200', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.029', 'spread': '0.021', 'groupId': 'OG000'}, {'value': '0.116', 'spread': '0.026', 'groupId': 'OG001'}, {'value': '0.099', 'spread': '0.026', 'groupId': 'OG002'}, {'value': '0.127', 'spread': '0.026', 'groupId': 'OG003'}, {'value': '0.111', 'spread': '0.026', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.145', 'ciLowerLimit': '0.102', 'ciUpperLimit': '0.188', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.128', 'ciLowerLimit': '0.085', 'ciUpperLimit': '0.171', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.156', 'ciLowerLimit': '0.113', 'ciUpperLimit': '0.198', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.140', 'ciLowerLimit': '0.098', 'ciUpperLimit': '0.182', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.022', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Peak FVC Within 24 Hours Post-dose Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.246', 'spread': '0.024', 'groupId': 'OG000'}, {'value': '0.382', 'spread': '0.030', 'groupId': 'OG001'}, {'value': '0.371', 'spread': '0.030', 'groupId': 'OG002'}, {'value': '0.390', 'spread': '0.030', 'groupId': 'OG003'}, {'value': '0.373', 'spread': '0.029', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.136', 'ciLowerLimit': '0.084', 'ciUpperLimit': '0.187', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.026', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.124', 'ciLowerLimit': '0.073', 'ciUpperLimit': '0.176', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.026', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.144', 'ciLowerLimit': '0.093', 'ciUpperLimit': '0.195', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.026', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.126', 'ciLowerLimit': '0.075', 'ciUpperLimit': '0.177', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.026', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post-dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Trough FVC Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.013', 'spread': '0.024', 'groupId': 'OG000'}, {'value': '0.096', 'spread': '0.031', 'groupId': 'OG001'}, {'value': '0.079', 'spread': '0.031', 'groupId': 'OG002'}, {'value': '0.105', 'spread': '0.031', 'groupId': 'OG003'}, {'value': '0.098', 'spread': '0.031', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.110', 'ciLowerLimit': '0.055', 'ciUpperLimit': '0.165', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.028', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '0.0010', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.092', 'ciLowerLimit': '0.037', 'ciUpperLimit': '0.147', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.028', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.118', 'ciLowerLimit': '0.063', 'ciUpperLimit': '0.172', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.028', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.111', 'ciLowerLimit': '0.057', 'ciUpperLimit': '0.166', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.028', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FVC values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '200', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.101', 'spread': '0.060', 'groupId': 'OG000'}, {'value': '0.730', 'spread': '0.075', 'groupId': 'OG001'}, {'value': '0.703', 'spread': '0.075', 'groupId': 'OG002'}, {'value': '0.732', 'spread': '0.074', 'groupId': 'OG003'}, {'value': '0.787', 'spread': '0.074', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.629', 'ciLowerLimit': '0.500', 'ciUpperLimit': '0.757', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.065', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.601', 'ciLowerLimit': '0.473', 'ciUpperLimit': '0.730', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.065', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.631', 'ciLowerLimit': '0.503', 'ciUpperLimit': '0.758', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.065', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.685', 'ciLowerLimit': '0.558', 'ciUpperLimit': '0.813', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.065', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.', 'unitOfMeasure': 'Liter/sec', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.135', 'spread': '0.061', 'groupId': 'OG000'}, {'value': '0.530', 'spread': '0.077', 'groupId': 'OG001'}, {'value': '0.430', 'spread': '0.076', 'groupId': 'OG002'}, {'value': '0.567', 'spread': '0.076', 'groupId': 'OG003'}, {'value': '0.464', 'spread': '0.076', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.665', 'ciLowerLimit': '0.532', 'ciUpperLimit': '0.799', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.068', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.564', 'ciLowerLimit': '0.431', 'ciUpperLimit': '0.698', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.068', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.702', 'ciLowerLimit': '0.569', 'ciUpperLimit': '0.835', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.068', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.599', 'ciLowerLimit': '0.467', 'ciUpperLimit': '0.732', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.067', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.', 'unitOfMeasure': 'Liter/sec', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '200', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.014', 'spread': '0.059', 'groupId': 'OG000'}, {'value': '0.627', 'spread': '0.073', 'groupId': 'OG001'}, {'value': '0.563', 'spread': '0.073', 'groupId': 'OG002'}, {'value': '0.653', 'spread': '0.073', 'groupId': 'OG003'}, {'value': '0.629', 'spread': '0.073', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.641', 'ciLowerLimit': '0.516', 'ciUpperLimit': '0.765', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.063', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.577', 'ciLowerLimit': '0.453', 'ciUpperLimit': '0.701', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.063', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.667', 'ciLowerLimit': '0.544', 'ciUpperLimit': '0.790', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.063', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.643', 'ciLowerLimit': '0.519', 'ciUpperLimit': '0.766', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.063', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.', 'unitOfMeasure': 'Liter/sec', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Peak PEF Within 24 Hours Post-dose Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.663', 'spread': '0.068', 'groupId': 'OG000'}, {'value': '1.254', 'spread': '0.087', 'groupId': 'OG001'}, {'value': '1.185', 'spread': '0.087', 'groupId': 'OG002'}, {'value': '1.257', 'spread': '0.086', 'groupId': 'OG003'}, {'value': '1.286', 'spread': '0.086', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.591', 'ciLowerLimit': '0.436', 'ciUpperLimit': '0.746', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.079', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.522', 'ciLowerLimit': '0.366', 'ciUpperLimit': '0.677', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.079', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.594', 'ciLowerLimit': '0.439', 'ciUpperLimit': '0.749', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.079', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.623', 'ciLowerLimit': '0.468', 'ciUpperLimit': '0.777', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.079', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter/sec', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Trough PEF Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.009', 'spread': '0.062', 'groupId': 'OG000'}, {'value': '0.520', 'spread': '0.078', 'groupId': 'OG001'}, {'value': '0.401', 'spread': '0.078', 'groupId': 'OG002'}, {'value': '0.594', 'spread': '0.077', 'groupId': 'OG003'}, {'value': '0.472', 'spread': '0.077', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.529', 'ciLowerLimit': '0.396', 'ciUpperLimit': '0.662', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.068', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.410', 'ciLowerLimit': '0.277', 'ciUpperLimit': '0.543', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.068', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.603', 'ciLowerLimit': '0.471', 'ciUpperLimit': '0.736', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.067', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '0.481', 'ciLowerLimit': '0.349', 'ciUpperLimit': '0.613', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.067', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 PEF values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter/sec', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Mean Pre-dose Morning PEF (PEF a.m.)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '395.36', 'spread': '2.857', 'groupId': 'OG000'}, {'value': '428.32', 'spread': '3.586', 'groupId': 'OG001'}, {'value': '427.99', 'spread': '3.575', 'groupId': 'OG002'}, {'value': '427.02', 'spread': '3.562', 'groupId': 'OG003'}, {'value': '424.26', 'spread': '3.562', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '32.957', 'ciLowerLimit': '26.709', 'ciUpperLimit': '39.206', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.180', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '32.632', 'ciLowerLimit': '26.409', 'ciUpperLimit': '38.855', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.167', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '31.660', 'ciLowerLimit': '25.448', 'ciUpperLimit': '37.872', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.161', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '28.895', 'ciLowerLimit': '22.683', 'ciUpperLimit': '35.107', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.161', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'PEF a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter/min', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Mean Pre-dose Evening PEF (PEF p.m.)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '409.93', 'spread': '2.717', 'groupId': 'OG000'}, {'value': '438.80', 'spread': '3.418', 'groupId': 'OG001'}, {'value': '441.98', 'spread': '3.407', 'groupId': 'OG002'}, {'value': '441.74', 'spread': '3.395', 'groupId': 'OG003'}, {'value': '443.25', 'spread': '3.395', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '28.870', 'ciLowerLimit': '22.884', 'ciUpperLimit': '34.856', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.046', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '32.056', 'ciLowerLimit': '26.094', 'ciUpperLimit': '38.018', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.034', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '31.816', 'ciLowerLimit': '25.864', 'ciUpperLimit': '37.767', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.028', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '33.327', 'ciLowerLimit': '27.375', 'ciUpperLimit': '39.278', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.028', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'PEF p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Liter/min', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'PEF Daily Variability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '10.157', 'spread': '0.288', 'groupId': 'OG000'}, {'value': '8.576', 'spread': '0.371', 'groupId': 'OG001'}, {'value': '8.732', 'spread': '0.369', 'groupId': 'OG002'}, {'value': '8.419', 'spread': '0.368', 'groupId': 'OG003'}, {'value': '9.468', 'spread': '0.368', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-1.581', 'ciLowerLimit': '-2.262', 'ciUpperLimit': '-0.900', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.346', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-1.426', 'ciLowerLimit': '-2.104', 'ciUpperLimit': '-0.748', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.345', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-1.738', 'ciLowerLimit': '-2.415', 'ciUpperLimit': '-1.062', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.344', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '0.0458', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.689', 'ciLowerLimit': '-1.366', 'ciUpperLimit': '-0.013', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.344', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'PEF daily variability was assessed by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Percentage', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Mean Pre-dose Morning FEV1 (FEV1 a.m.)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '2425.1', 'spread': '17.870', 'groupId': 'OG000'}, {'value': '2598.5', 'spread': '22.276', 'groupId': 'OG001'}, {'value': '2580.2', 'spread': '22.208', 'groupId': 'OG002'}, {'value': '2574.3', 'spread': '22.133', 'groupId': 'OG003'}, {'value': '2575.5', 'spread': '22.133', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '173.391', 'ciLowerLimit': '135.099', 'ciUpperLimit': '211.682', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.484', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '155.097', 'ciLowerLimit': '116.961', 'ciUpperLimit': '193.234', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.406', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '149.268', 'ciLowerLimit': '111.204', 'ciUpperLimit': '187.333', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.369', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '150.441', 'ciLowerLimit': '112.377', 'ciUpperLimit': '188.505', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.369', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'FEV1 a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Mean Pre-dose Evening FEV1 (FEV1 p.m.)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '2474.3', 'spread': '17.692', 'groupId': 'OG000'}, {'value': '2616.6', 'spread': '21.949', 'groupId': 'OG001'}, {'value': '2606.5', 'spread': '21.884', 'groupId': 'OG002'}, {'value': '2616.5', 'spread': '21.810', 'groupId': 'OG003'}, {'value': '2631.7', 'spread': '21.809', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '142.251', 'ciLowerLimit': '104.916', 'ciUpperLimit': '179.586', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '18.997', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '132.138', 'ciLowerLimit': '94.954', 'ciUpperLimit': '169.322', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '18.920', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '142.136', 'ciLowerLimit': '105.021', 'ciUpperLimit': '179.251', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '18.885', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '157.306', 'ciLowerLimit': '120.192', 'ciUpperLimit': '194.420', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '18.885', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'FEV1 p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Mean Number of Puffs of Rescue Medication During the Whole Day', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.665', 'spread': '0.091', 'groupId': 'OG000'}, {'value': '1.110', 'spread': '0.120', 'groupId': 'OG001'}, {'value': '1.028', 'spread': '0.119', 'groupId': 'OG002'}, {'value': '1.077', 'spread': '0.119', 'groupId': 'OG003'}, {'value': '1.119', 'spread': '0.119', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.554', 'ciLowerLimit': '-0.780', 'ciUpperLimit': '-0.329', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.115', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.637', 'ciLowerLimit': '-0.862', 'ciUpperLimit': '-0.412', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.114', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.588', 'ciLowerLimit': '-0.813', 'ciUpperLimit': '-0.364', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.114', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.546', 'ciLowerLimit': '-0.770', 'ciUpperLimit': '-0.322', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.114', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM3 device (overall mean number obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.', 'unitOfMeasure': 'Puffs', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Percentage of Asthma Symptom Free Days', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '23.630', 'spread': '2.235', 'groupId': 'OG000'}, {'value': '33.929', 'spread': '3.554', 'groupId': 'OG001'}, {'value': '36.306', 'spread': '3.644', 'groupId': 'OG002'}, {'value': '28.844', 'spread': '3.271', 'groupId': 'OG003'}, {'value': '28.049', 'spread': '3.368', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': '0-3 weeks', 'description': 'Percentage of asthma-symptom free days of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM3 device.', 'unitOfMeasure': 'Percentage of asthma symptom free days', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'title': 'Did not wake up', 'categories': [{'measurements': [{'value': '93', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '53', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}, {'value': '47', 'groupId': 'OG004'}]}]}, {'title': 'Woke up once', 'categories': [{'measurements': [{'value': '67', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '36', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}, {'value': '32', 'groupId': 'OG004'}]}]}, {'title': 'Woke up 2-5 times', 'categories': [{'measurements': [{'value': '36', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}]}, {'title': 'Woke up > 5 times', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Was awake all night', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '0-3 weeks', 'description': 'Assessed by patients at home using the AM3 device during each period of randomised treatment.', 'unitOfMeasure': 'Number of patients', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'title': 'No asthma symptoms', 'categories': [{'measurements': [{'value': '31', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}, {'value': '20', 'groupId': 'OG004'}]}]}, {'title': 'Mild asthma symptoms', 'categories': [{'measurements': [{'value': '66', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}]}]}, {'title': 'Moderate asthma symptoms', 'categories': [{'measurements': [{'value': '85', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '37', 'groupId': 'OG004'}]}]}, {'title': 'Severe asthma symptoms', 'categories': [{'measurements': [{'value': '18', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Very severe asthma symptoms', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '0-3 weeks', 'description': 'Assessed by patients at home using the AM3 device during each period of randomised treatment .', 'unitOfMeasure': 'Number of patients', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'title': 'No asthma symptoms', 'categories': [{'measurements': [{'value': '39', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}, {'value': '21', 'groupId': 'OG003'}, {'value': '21', 'groupId': 'OG004'}]}]}, {'title': 'Mild asthma symptoms', 'categories': [{'measurements': [{'value': '76', 'groupId': 'OG000'}, {'value': '35', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}]}]}, {'title': 'Moderate asthma symptoms', 'categories': [{'measurements': [{'value': '74', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '29', 'groupId': 'OG003'}, {'value': '35', 'groupId': 'OG004'}]}]}, {'title': 'Severe asthma symptoms', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}]}]}, {'title': 'Very severe asthma symptoms', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '0-3 weeks', 'description': 'Assessed by patients at home using the AM3 device during each period of randomised treatment.', 'unitOfMeasure': 'Number of patients', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Total Asthma Control Questionnaire (ACQ) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '101', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.613', 'spread': '0.040', 'groupId': 'OG000'}, {'value': '1.256', 'spread': '0.053', 'groupId': 'OG001'}, {'value': '1.317', 'spread': '0.053', 'groupId': 'OG002'}, {'value': '1.312', 'spread': '0.053', 'groupId': 'OG003'}, {'value': '1.311', 'spread': '0.053', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.357', 'ciLowerLimit': '-0.461', 'ciUpperLimit': '-0.253', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.053', 'estimateComment': 'Olo 2.5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.296', 'ciLowerLimit': '-0.400', 'ciUpperLimit': '-0.192', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.053', 'estimateComment': 'Olo 5 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.301', 'ciLowerLimit': '-0.405', 'ciUpperLimit': '-0.198', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.053', 'estimateComment': 'Olo 5 mcg bid minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Mean Difference (Final Values)', 'ciPctValue': '95', 'paramValue': '-0.302', 'ciLowerLimit': '-0.405', 'ciUpperLimit': '-0.198', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.053', 'estimateComment': 'Olo 10 mcg qd minus Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '3 weeks', 'description': 'Control of asthma as assessed by the ACQ at the end of each 3-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS'}, {'type': 'SECONDARY', 'title': 'Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}, {'value': '101', 'groupId': 'OG003'}, {'value': '102', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).'}, {'id': 'OG001', 'title': 'Olo 2.5 mcg Bid', 'description': 'Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG002', 'title': 'Olo 5 mcg qd', 'description': 'Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}, {'id': 'OG003', 'title': 'Olo 5 mcg Bid', 'description': 'Olodaterol 5 mcg bid delivered by the Respimat Inhaler.'}, {'id': 'OG004', 'title': 'Olo 10 mcg qd', 'description': 'Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.'}], 'classes': [{'title': 'Atrioventricular block first degree', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Sinus tachycardia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Aspartate aminotransferase increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Blood creatinine increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Blood glucose increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Blood urea abnormal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Gamma-glutamyltransferase increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Blood creatine phosphokinase increased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Blood urine present', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Anaemia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Hypertension', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '3 weeks + 12 days', 'description': 'Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Treated set'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Study Total', 'description': 'This was a double-blind, 3-period crossover trial. 206 patients were assigned randomly to one of 12 treatment sequences with either 5 microgram (mcg) Olodaterol (Olo) once daily (qd) and 2.5 mcg Olodaterol twice daily (bid) and placebo (6 sequences) or 10 mcg Olodaterol qd and 5 mcg Olodaterol bid and placebo (6 sequences). The duration of each treatment period was 3 weeks separated by washout periods of 2 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Entered and treated', 'groupId': 'FG000', 'numSubjects': '206'}]}, {'type': 'Received Placebo', 'achievements': [{'groupId': 'FG000', 'numSubjects': '201'}]}, {'type': 'Received Olo 2.5 mcg Bid', 'achievements': [{'groupId': 'FG000', 'numSubjects': '101'}]}, {'type': 'Received Olo 5 mcg qd', 'achievements': [{'groupId': 'FG000', 'numSubjects': '101'}]}, {'type': 'Received Olo 5 mcg Bid', 'achievements': [{'groupId': 'FG000', 'numSubjects': '101'}]}, {'type': 'Received Olo 10 mcg qd', 'achievements': [{'groupId': 'FG000', 'numSubjects': '102'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '199'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '206', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Study Total', 'description': 'This was a double-blind, 3-period crossover trial. 206 patients were assigned randomly to one of 12 treatment sequences with either 5 microgram (mcg) Olodaterol (Olo) once daily (qd) and 2.5 mcg Olodaterol twice daily (bid) and placebo (6 sequences) or 10 mcg Olodaterol qd and 5 mcg Olodaterol bid and placebo (6 sequences). The duration of each treatment period was 3 weeks separated by washout periods of 2 weeks.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.7', 'spread': '12.2', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '109', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '97', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 206}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-03', 'lastUpdateSubmitDate': '2014-03-28', 'studyFirstSubmitDate': '2011-03-04', 'resultsFirstSubmitDate': '2014-03-28', 'studyFirstSubmitQcDate': '2011-03-08', 'lastUpdatePostDateStruct': {'date': '2014-05-01', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2014-03-28', 'studyFirstPostDateStruct': {'date': '2011-03-09', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2014-05-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.'}], 'secondaryOutcomes': [{'measure': 'FEV1 Area Under Curve 0-12 Hours (AUC 0-12h) Response at the End of Each Treatment Period', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.'}, {'measure': 'FEV1 Area Under Curve 12-24 Hours (AUC 12-24h) Response at the End of Each Treatment Period', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.'}, {'measure': 'Peak FEV1 Within 24 Hours Post-dose Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Trough FEV1 Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.'}, {'measure': 'FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.'}, {'measure': 'FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.'}, {'measure': 'Peak FVC Within 24 Hours Post-dose Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post-dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Trough FVC Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FVC values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.'}, {'measure': 'PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.'}, {'measure': 'Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.'}, {'measure': 'Peak PEF Within 24 Hours Post-dose Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Trough PEF Response', 'timeFrame': '1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks', 'description': 'Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 PEF values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Mean Pre-dose Morning PEF (PEF a.m.)', 'timeFrame': '0-3 weeks', 'description': 'PEF a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Mean Pre-dose Evening PEF (PEF p.m.)', 'timeFrame': '0-3 weeks', 'description': 'PEF p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'PEF Daily Variability', 'timeFrame': '0-3 weeks', 'description': 'PEF daily variability was assessed by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Mean Pre-dose Morning FEV1 (FEV1 a.m.)', 'timeFrame': '0-3 weeks', 'description': 'FEV1 a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Mean Pre-dose Evening FEV1 (FEV1 p.m.)', 'timeFrame': '0-3 weeks', 'description': 'FEV1 p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Mean Number of Puffs of Rescue Medication During the Whole Day', 'timeFrame': '0-3 weeks', 'description': 'Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM3 device (overall mean number obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.'}, {'measure': 'Percentage of Asthma Symptom Free Days', 'timeFrame': '0-3 weeks', 'description': 'Percentage of asthma-symptom free days of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM3 device.'}, {'measure': 'Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)', 'timeFrame': '0-3 weeks', 'description': 'Assessed by patients at home using the AM3 device during each period of randomised treatment.'}, {'measure': 'Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)', 'timeFrame': '0-3 weeks', 'description': 'Assessed by patients at home using the AM3 device during each period of randomised treatment .'}, {'measure': 'Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)', 'timeFrame': '0-3 weeks', 'description': 'Assessed by patients at home using the AM3 device during each period of randomised treatment.'}, {'measure': 'Total Asthma Control Questionnaire (ACQ) Score', 'timeFrame': '3 weeks', 'description': 'Control of asthma as assessed by the ACQ at the end of each 3-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.'}, {'measure': 'Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG', 'timeFrame': '3 weeks + 12 days', 'description': 'Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.'}]}, 'conditionsModule': {'conditions': ['Asthma']}, 'referencesModule': {'references': [{'pmid': '26177937', 'type': 'DERIVED', 'citation': 'Beeh KM, LaForce C, Gahlemann M, Wenz A, Toorawa R, Flezar M. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat(R) in patients with moderate to severe persistent asthma. Respir Res. 2015 Jul 16;16(1):87. doi: 10.1186/s12931-015-0243-1.'}]}, 'descriptionModule': {'briefSummary': 'This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n1. Patients of either sex.\n2. Aged 18 to 70 years.\n3. A current diagnosis and a documented minimum 3 month history of asthma Global Initiative for Asthma (GINA) treatment steps 3 and 4.\n4. Prebronchodilator Forced Expiratory Volume in one second (FEV1) \\>= 60% predicted and \\< 90% predicted according to European Coal and Steel Community (ECSC).\n5. Increase in FEV1 \\>=12% and \\>=200 mL 15 min. after 400 µg salbutamol (albuterol);\n6. Stable on medium to high dose inhaled corticosteroids (ICS) or low to high dose ICS in combination with a long acting beta-adrenergics (LABA) for at least 6 weeks prior to screening. Stable on ICS mono component of the former fixed LABA/ICS treatment for at least 48 hours prior to Visit 1b.\n\nExclusion criteria:\n\n1. Patients with a significant disease other than asthma.\n2. History of frequent seasonal exacerbations of asthma (defined as one or more seasonal exacerbations every year for the past three years).\n3. Upper respiratory tract infection in the past 3 weeks prior to screening visit 1b.\n4. Oral or other systemic corticosteroids in the past 6 weeks.\n5. Patients with allergen desensitization therapy if started within two years, if they are not on an established maintenance regimen characterized by dose adjustments but no further increase to the tolerable maximum in the same course of immunotherapy.'}, 'identificationModule': {'nctId': 'NCT01311661', 'briefTitle': 'A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma', 'orgStudyIdInfo': {'id': '1222.29'}, 'secondaryIdInfos': [{'id': '2008-006625-14', 'type': 'EUDRACT_NUMBER', 'domain': 'EudraCT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Olodaterol medium daily dose', 'description': 'Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases', 'interventionNames': ['Drug: Olodaterol low daily dose twice daily', 'Drug: Placebo twice daily', 'Drug: Olodaterol medium daily dose once daily and placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Olodaterol high daily dose', 'description': 'Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases', 'interventionNames': ['Drug: Placebo twice daily', 'Drug: Olodaterol medium daily dose twice daily', 'Drug: Olodaterol high daily dose once daily and placebo']}], 'interventions': [{'name': 'Placebo twice daily', 'type': 'DRUG', 'description': 'Inhaled Placebo of Olodaterol twice daily', 'armGroupLabels': ['Olodaterol high daily dose']}, {'name': 'Olodaterol low daily dose twice daily', 'type': 'DRUG', 'description': 'Inhaled Olodaterol medium daily dose administered as low dose twice daily', 'armGroupLabels': ['Olodaterol medium daily dose']}, {'name': 'Olodaterol medium daily dose twice daily', 'type': 'DRUG', 'description': 'Inhaled Olodaterol high daily dose administered as medium dose twice daily', 'armGroupLabels': ['Olodaterol high daily dose']}, {'name': 'Placebo twice daily', 'type': 'DRUG', 'description': 'Inhaled Placebo of Olodaterol twice daily', 'armGroupLabels': ['Olodaterol medium daily dose']}, {'name': 'Olodaterol high daily dose once daily and placebo', 'type': 'DRUG', 'description': 'Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily', 'armGroupLabels': ['Olodaterol high daily dose']}, {'name': 'Olodaterol medium daily dose once daily and placebo', 'type': 'DRUG', 'description': 'Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily', 'armGroupLabels': ['Olodaterol medium daily dose']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Huntington Beach', 'state': 'California', 'country': 'United States', 'facility': '1222.29.11006 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 33.6603, 'lon': -117.99923}}, {'city': 'Centennial', 'state': 'Colorado', 'country': 'United States', 'facility': '1222.29.11001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 39.57916, 'lon': -104.87692}}, {'city': 'Wheat Ridge', 'state': 'Colorado', 'country': 'United States', 'facility': '1222.29.11012 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 39.7661, 'lon': -105.07721}}, {'city': 'Overland Park', 'state': 'Kansas', 'country': 'United States', 'facility': '1222.29.11002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'city': 'North Dartmouth', 'state': 'Massachusetts', 'country': 'United States', 'facility': '1222.29.11004 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 41.63899, 'lon': -70.97032}}, {'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': '1222.29.11011 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'city': 'Skillman', 'state': 'New Jersey', 'country': 'United States', 'facility': '1222.29.11009 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.42011, 'lon': -74.7146}}, {'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': '1222.29.11003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'city': 'Canton', 'state': 'Ohio', 'country': 'United States', 'facility': '1222.29.11008 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.79895, 'lon': -81.37845}}, {'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': '1222.29.11007 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'city': 'Spartanburg', 'state': 'South Carolina', 'country': 'United States', 'facility': '1222.29.11005 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 34.94957, 'lon': -81.93205}}, {'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': '1222.29.11010 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'city': 'Linz', 'country': 'Austria', 'facility': '1222.29.43003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}, {'city': 'Schlüsslberg', 'country': 'Austria', 'facility': '1222.29.43002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.21861, 'lon': 13.87161}}, {'city': 'Thalheim bei Wels', 'country': 'Austria', 'facility': '1222.29.43001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.15, 'lon': 14.03333}}, {'city': 'Wels', 'country': 'Austria', 'facility': '1222.29.43004 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.16667, 'lon': 14.03333}}, {'city': 'Berlin', 'country': 'Germany', 'facility': '1222.29.49004 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Berlin', 'country': 'Germany', 'facility': '1222.29.49006 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Berlin', 'country': 'Germany', 'facility': '1222.29.49007 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Berlin', 'country': 'Germany', 'facility': '1222.29.49008 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Frankfurt', 'country': 'Germany', 'facility': '1222.29.49002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.68333, 'lon': 10.53333}}, {'city': 'Großhansdorf', 'country': 'Germany', 'facility': '1222.29.49010 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 53.66528, 'lon': 10.28552}}, {'city': 'Lübeck', 'country': 'Germany', 'facility': '1222.29.49003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'city': 'Rüdersdorf', 'country': 'Germany', 'facility': '1222.29.49005 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 52.46927, 'lon': 13.78631}}, {'city': 'Wiesbaden', 'country': 'Germany', 'facility': '1222.29.49001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.08601, 'lon': 8.24435}}, {'city': 'Wiesloch', 'country': 'Germany', 'facility': '1222.29.49009 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.29504, 'lon': 8.69846}}, {'city': 'Mosonmagyaróvár', 'country': 'Hungary', 'facility': '1222.29.36002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 47.86789, 'lon': 17.26994}}, {'city': 'Nyíregyháza', 'country': 'Hungary', 'facility': '1222.29.36003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'city': 'Sopron', 'country': 'Hungary', 'facility': '1222.29.36001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 47.68501, 'lon': 16.59049}}, {'city': 'Zalaegerszeg', 'country': 'Hungary', 'facility': '1222.29.36004 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 46.83695, 'lon': 16.84401}}, {'city': 'Bardejov', 'country': 'Slovakia', 'facility': '1222.29.42001 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.29175, 'lon': 21.27271}}, {'city': 'Martin', 'country': 'Slovakia', 'facility': '1222.29.42002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.06651, 'lon': 18.92399}}, {'city': 'Nitra', 'country': 'Slovakia', 'facility': '1222.29.42004 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.30763, 'lon': 18.08453}}, {'city': 'Spišská Nová Ves', 'country': 'Slovakia', 'facility': '1222.29.42003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.94464, 'lon': 20.56153}}, {'city': 'Golnik', 'country': 'Slovenia', 'facility': '1222.29.38003 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 46.33333, 'lon': 14.33333}}, {'city': 'Kamnik', 'country': 'Slovenia', 'facility': '1222.29.38002 Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 46.22587, 'lon': 14.61207}}], 'overallOfficials': [{'name': 'Boehringer Ingelheim', 'role': 'STUDY_CHAIR', 'affiliation': 'Boehringer Ingelheim'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}